Frederick St Goar, MD
Interventional Cardiology · Mountain View, CANPI 1992710453
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,086,907 of the $2,208,674 with a category attached, or 94.5%. Alydia Health accounts for 93.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $2,112,376 and has fallen 99.7% since, to $5,742 in 2025. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $16,483 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alydia Health$2.1M
- Abbott$87K
- Boston Scientific$46K
- Heartflow, Inc.$11K
- Medtronic$320
- Amgen$257
- plus $596 from 15 others
Across 13 payments — averaging $155,155 each. An ownership or investment interest held by the physician or an immediate family member.
- Heartflow, Inc.$2M
- Alydia Health$0
What the payments were for
- Royalty or licence$1,5000%
- Consulting fees$2,086,90794%
- Speaking & faculty fees$29,2001%
- Grants$660%
- Travel & lodging$40,9342%
- Food & beverage$3,9750%
- Other$46,0912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alydia Health | 2 | $2,063,507 |
| Abbott | 57 | $86,581 |
| Boston Scientific | 4 | $46,127 |
| Heartflow, Inc. | 29 | $11,284 |
| Medtronic(2 entities) | 4 | $320 |
| Amgen | 11 | $257 |
| Boehringer Ingelheim | 4 | $99 |
| Pfizer | 4 | $96 |
| Novartis | 4 | $77 |
| Alnylam Pharmaceuticals Inc. | 3 | $70 |
| Merck | 2 | $54 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
| Bardy Diagnostics, Inc. | 1 | $22 |
| AstraZeneca | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Cordis US CORP. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Octapharma USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JADA SYSTEM$2,063,507
- MitraClip$67,106
- GENERAL - THERAPIES$46,091
- FFRct$11,005
- TENDYNE$4,750
- FreeStyle Libre$1,400
- Mitra Clip system$652
- OPTIS$204
- Quadra Assura CRT Defibrillator$123
- AURORA EV-ICD MRI SURESCAN$113
- AMPLATZER TALISMAN$113
How this compares
$2,208,674 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $37,922 |
| Repatha SureclickEvolocumab | 11 | $13,547 |
| Rosuvastatin Calcium | 78 | $1,063 |
| Atorvastatin Calcium | 65 | $1,019 |
| Ezetimibe | 23 | $874 |
| Metoprolol Succinate | 38 | $678 |
| Losartan Potassium | 36 | $575 |
| Potassium Chloride | 25 | $461 |
| Nitroglycerin | 26 | $387 |
| ClopidogrelClopidogrel Bisulfate | 21 | $273 |
| Furosemide | 31 | $241 |
| Metoprolol Tartrate | 24 | $213 |
| Carvedilol | 18 | $133 |
| Amlodipine Besylate | 19 | $56 |
| Hydrochlorothiazide | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $96 | $37,92227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Mountain View
- Chidambaram RammohanMountain View$232K
- Matthew Pricela Jolla$2.3M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.